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Abstract
Background: Recently, hepcidin expression in adipose tissue has been described and shown to be increased in
patients with severe obesity. We tried to assess the effect of obesity on hepcidin serum levels and treatment
outcome of iron deficiency anemia in children.
Methods: This was a case control study included 70 children with iron deficiency anemia “IDA” (35 obese and 35
non-obese) and 30 healthy non-obese children with comparable age and sex(control group). Parameters of iron
status (Serum iron, ferritin, transferrin, total iron binding capacity and transferrin saturation) and serum hepcidin
levels were assessed initially and after 3 months of oral iron therapy for IDA.
Results: Compared to the control group, serum hepcidin was significantly lower in non-obese children with IDA(p
< 0.01) and significantly higher in obese children with IDA (p < 0.01). Hepcidin increased significantly in non-obese
children with IDA after 3 months of iron therapy (P < 0.01). On the other hand, obese children showed non-
significant change in hepcidin level after iron therapy (p > 0.05). Although hepcidin showed significant positive
correlations with Hb, serum iron and transferrin saturation in non-obese children with IDA, it showed significant
negative correlations with Hb, serum iron and transferrin saturation in obese children with IDA (P < 0.05).
Conclusions: Obesity increased hepcidin levels and was associated with diminished response to oral iron therapy
in childhood iron deficiency anemia.
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Background
Obesity is associated with low-serum iron concentra-
tions. The inverse relationship between iron status and
adiposity was first reported in 1962, when Wenzel et al
[1] unexpectedly found a significantly lower mean
serum iron concentration in obese compared with non-
obese adolescents. Most subsequent studies in pediatric
and adult samples have shown similar results [2-5].
The etiology of the hypoferremia of obesity is uncer-
tain. Among the proposed causes are deficient iron
intake from an iron poor diet [2], and deficient iron
stores owing to greater iron requirements in obese
adults because of their larger blood volume [6].
Recently, fat mass was described as a significant negative
predictor of serum iron and this hypoferremia seemed
not to be explained by differences in iron intake [7].
Adipose tissue is a very active endocrine organ secret-
ing numerous hormones and cytokines associated with
important systemic effects on different metabolic pro-
cesses [8]. Recently, hepcidin expression in adipose tissue
has been described and shown to be increased in patients
with severe obesity [9]. Hepcidin is a small, cysteine-rich
cationic peptide produced by hepatocytes [10,11],
secreted into plasma, and excreted in urine. Hepcidin
expression is induced by iron stores and inflammation
[11] and is suppressed by hypoxia and anemia [12]. Hep-
cidin is proposed to be a key regulator of iron metabo-
lism and its discovery has changed our understanding of
the pathophysiology of iron disorders [10]. Adipose tissue
of obese patients produced increased amount of* Correspondence: zanad_zanad2005@yahoo.com
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proinflammatory cytokines contributing to the develop-
ment of a low-grade systemic inflammation in these
patients [13].
At present, regulatory pathways that are generally
thought to control liver hepcidin production include: (i)
iron store-related regulation (ii) erythropoietic activity
driven regulation, and (iii) inflammation related regula-
tion. All are found to interact with liver cells to initiate
the production of sufficient hepcidin for correct mainte-
nance of iron homeostasis [14-17]. The aim of this
study was to assess the effect of obesity on hepcidin
serum levels and its relation to treatment outcome of
iron deficiency anemia in children.
Methods
This was a prospective case control study performed in
Zagazig University Children Hospital and Outpatient
Clinics in the same Hospital from April 2009 to August
2010. Informed parental consent was obtained for
enrollment into the study. The study was done accord-
ing to the rules of the local ethics committee of Faculty
of medicine, Zagazig University. The study included 70
children with iron deficiency anemia [35 obese with
BMI ≥ 95thcentile for age and sex and 35 non-obese
with BMI < 85thcentile for age and sex]. 30 healthy non-
obese children of comparable age and sex served as a
control group.
Iron deficiency was defined as presence of one or
more abnormal age-corrected iron parameters (iron,
ferritin, transferrin and transferrin saturation). IDA
was defined as concurrent iron deficiency and anemia
[18].
We excluded from the study all patients with infec-
tions, collagen diseases, liver diseases, renal diseases, as
will as children who received iron therapy in the pre-
vious three months.
The following was done for patients and control group
1-Full history taking and detailed clinical examination
including anthropometric measurements and body mass
index (BMI) calculation.
2-Routine laboratory investigations including urinaly-
sis, stool analysis, complete blood count (CBC) includ-
ing blood indices, ESR and C-reactive protein (CRP).
3-Urine culture and sensitivity.
4-Liver function and kidney function tests.
5-Estimation of iron parameters (serum iron, ferritin,
transferrin, total iron binding capacity (TIBC) and trans-
ferrin saturation).
6-Estimation of serum hepcidin-25 levels.
CBC, iron parameters and serum hepcidin-25 were re-
evaluated for all children with IDA after three months-
treatment course of anemia by oral ferrous sulfate (5
mg/kg/day of elemental iron).
Serum hepcidin assay: Hepcidin C-ELISA
Before hepcidin analysis, sera were separated and stored
frozen at 80°C at the Department of Biochemistry till
the time of assay. According to the manufacturer’s pro-
tocol; 96-well plates were coated with the antibody to
human hepcidin and incubated with 100 μL (standard
samples) or 200 μL (samples with very low concentra-
tion of hepcidin) of 1:20 dilution of serum in Tris-buf-
fered saline containing 0.05% Tween-20 (TBS-Tween
20), with 10 ng/mL of biotinylated hepcidin-25 (Intrinsic
LifeSciences, La Jolla, CA) added as the tracer. Standard
curves were prepared by serial 2-fold dilution of syn-
thetic hepcidin (Bachem Biosciences, King of Prussia,
PA) 4000 ng/mL in TBS-Tween 20 buffer containing
the tracer. The integrity and bioactivity of synthetic
hepcidin and biotinylated hepcidin were verified by
spectrometry and by bioassay with ferroportin-green
fluorescent protein expressing HEK-293 cells [19]. After
washing, the assay was developed with streptavidin-per-
oxidase and tetramethyl benzidine. The enzymatic reac-
tion was stopped by sulfuric acid, and the plate was
read at 450 nm on a DTX 880 microplate reader (Beck-
man Coulter, Fullerton, CA). Standard curves were fitted
with 12-point fit using GraphPad Prism software
(GraphPad Software, San Diego, CA). The fitted curve
was then used to convert sample absorbance readings to
hepcidin concentrations.
Statistical analysis
SPSS for windows, version 11; was used for data analy-
sis. Values were expressed as means ± SD. Chi-square
test, Student t test and ANOVA test were used. Multiple
comparison analysis by the least significant difference
(LSD) was used. This test detects statistical difference
between two means when ANOVA test refers to signifi-
cances. Correlation between variables was assessed. P <
0.05 was considered significant.
Results
There were non significant differences between the
study groups as regards age, sex; p > 0.05, respectively
(Table 1). BMI was significantly higher in obese
children with IDA compared to both non-obese children
with IDA and healthy control; p < 0,01, respectively
(Table 1). Hb, MCV, MCHC, serum iron and transferrin
saturation were all significantly lower in children with
IDA (obese and non-obese) compared to the control,
meanwhile there were non-significant differences
between obese and non-obese children with IDA regard-
ing these parameters; p > 0.05, respectively. Both TIBC
and transferrin were significantly higher in children with
IDA (obese and non-obese) compared to the healthy
control, meanwhile there were non-significant differ-
ences between obese and non-obese children with IDA
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regarding TIBC and transferrin; p > 0.05, respectively
(Table 1). Serum ferritin was significantly lower in non-
obese children with IDA (7.52 ± 1.6 ng/ml) compared
to both obese children with IDA (51.91 ± 8.7 ng/ml)
and healthy control group (56.19 ± 4.1 ng/ml), (p <
0.05, respectively). However, a non-significant difference
was found between serum ferritin in obese children with
IDA and that in healthy control (P > 0.05) (Table 1).
Serum hepcidin was significantly lower in non-obese
children with IDA (0.11 ± 0.03 nmol/l) compared to
both obese children with IDA (4.96 ± 1.2 nmol/l) and
healthy control group (1.61 ± 0.7 nmol/l); p < 0.01,
respectively. Meanwhile, serum hepcidin was signifi-
cantly higher in obese children with IDA compared to
healthy control group; (P < 0.05), (Table 1).
CRP was significantly higher in obese children with
IDA (5.71 ± 0.7 mg/dl) than in non-obese children with
IDA (2.42 ± 0.5 mg/dl) and healthy control group (2.53
± 0.6 mg/dl); P < 0.05, respectively, (Table 1). Mean-
while, there was no significant difference between non-
obese children with IDA and control group as regard
CRP; p > 0.05, (Table 1).
After three months of oral iron therapy, there were
significant improvement of Hb, serum iron and TIBC in
cases of IDA (P < 0.05), that was significantly more evi-
dent in non-obese children than in obese children (P <
0.05, respectively), (Table 2).
Serum ferritin increased significantly in non-obese
children with IDA after 3 months of iron therapy; (P <
0.01). On the other hand, there was non-significant dif-
ference between serum ferritin before and after iron
therapy in obese children (P > 0.05), (Table 2).
After oral iron therapy, there was non significant dif-
ference between patient groups and control group
regarding serum ferritin levels (Figure 1).
Serum hepcidin increased significantly in non-obese
children with IDA after 3 months of iron therapy (P <
0.01). On the other hand, there was non-significant change
in serum hepcidin level after iron therapy in obese chil-
dren (P > 0.05), (Table 2).
Despite oral iron therapy, serum hepcidin levels in
obese children persisted at significantly higher level than
the control group. On the other hand, hepcidin levels in
non-obese children were similar to that of the control
(Figure 2).
In non-obese children with IDA, serum hepcidin showed
significant positive correlations with Hb, serum iron and
transferrin saturation (r = 0.498, p < 0.01, r = 0.478, p <
0.01, r = 0.468, p < 0.01, respectively), (Table 3). On the
other hand, serum hepcidin showed significant negative
correlations with TIBC and transferrin (r = -0.411, p <
0.05, r = -0.398, p < 0.05, respectively), (Table 3).
On the contrary, in obese children with IDA, serum
hepcidin showed significant negative correlations with
Hb, serum iron and transferrin saturation(P < 0.05)
(Table 3). Otherwise it showed significant positive corre-
lations with TIBC and transferrin (P < 0.05), (Table 3).
Discussion
Recently, data from the American National Health and
Nutrition Examination Survey III as well as data obtained
in children from transition countries (Morocco and India)
have suggested that among children, the prevalence of
iron deficiency increases as BMI increases from normal
Table 1 Baseline clinical and laboratory data of patients and control group.
Obese children with IDA Non obese children with IDA Control P
(n = 35) (n = 35) (n = 30)
Age (years) 6.96 ± 2.2 7.11 ± 2.57 7.11 ± 2.57 >0.05
Male/female # 22/18 23/17 11/9 >0.05
BMI (kg/m2) 25.70 ± 2.2 a 16.30 ± 1.9 b 16.2 ± 1.7 b <0.05
Hb (g/dl) 8.82 ± 1.2 a 8.22 ± 1.4 a 13.0 ± 1.4 b <0.05
MCV (fl) 70.80 ±4.6 a 69.33 ± 4.0 a 92.33 ± 7.0 b <0.05
MCHC (%) 26.3 ± 2.3 a 25.6 ± 2.5 a 33.7 ± 2.6 b <0.05
Serum iron (ug/dl) 28.83 ± 2.5 a 29.28 ± 4.6 a 90.45 ± 4.4 b <0.05
TIBC (mg/dl) 491 ± 24 a 478 ± 15 a 258 ± 15 b <0.05
Transferrin saturation (%) 5.87 ± 0.9 a 6.13 ± 1.2 a 35.05 ± 1.7 b <0.05
Transferrin (umol/L) 75 ± 7.1 a 77 ± 6.8 a 34 ± 2.3 b <0.05
Ferritin (ng/ml) 51.91 ± 8.7 a 7.52 ± 1.6 b 56.19 ± 4.1 a <0.05
CRP (mg/dl) 5.71 ± 0.7 a 2.42 ± 0.5 b 2.53 ± 0.6 b <0.05
Serum hepcidin (nmol/l) 4.96 ± 1.2 a 0.11 ± 0.03 b 1.61 ± 0.7 c <0.05
The P value is for ANOVA. a, b and c on means refer to significant difference between means when ANOVA test refers to significances by multiple comparison
analysis (aa, bb, cc = non-significant, ab, ac, bc = significant). # Chi-square test.
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weight to at risk for obesity to obesity [20-23]. It remains
unclear, however, if the lower serum iron and elevated fer-
ritin seen in obesity are most reflective of a functional iron
deficiency related to an inflammatory state, or if obesity is
also a risk factor for true iron deficiency [24].
At the beginning of our study, obese children with
IDA had significantly higher serum ferritin levels than
non-obese children with IDA (p < 0.01), and were simi-
lar to ferritin levels in healthy children (P > 0.05).
Obesity is considered a chronic inflammatory state
[25]. Serum ferritin concentrations, which are usually
suppressed when body iron stores are low [26], tend to
be high and inversely related to transferrin saturation in
those with excessive adiposity. Ferritin is considered an
acute-phase reactant [24], hence, it may be elevated in
inflammatory conditions even in the presence of true
iron deficiency [26]. cytokines such as interleukin-1b
and tumor necrosis factor-a (TNF-a) induce ferritin
production within macrophages, hepatocytes and adipo-
cytes [27].
In our study, obese children with IDA had signifi-
cantly higher serum hepcidin levels (p < 0.01), in com-
parison to non-obese children with IDA and healthy
control group (P < 0.01), in contrast, non-obese children
with IDA had significantly lower serum hepcidin levels,
compared to obese children with IDA and healthy con-
trol children (P < 0.01).
Hepcidin is a small peptide hormone secreted by the
liver and by adipocytes [9]. Hepcidin is suppressed in
iron deficiency, allowing increased absorption of dietary
iron and replenishment of iron stores [28]. The feedback
loop between iron and hepcidin ensures stability of
plasma iron concentrations[29]. Hepcidin is an acute-
phase reactant [10,24], and its expression is increased in
chronic inflammatory states[30] including obesity [9].
Hepcidin can inhibit enterocyte iron absorption [31]
and has further been shown to inhibit the release of
non-heme iron from macrophages [32]. Because each of
these actions diminishes the amount of bioavailable
body iron, it has been suggested that when hepcidin
is induced by inflammation, hepcidin is a key iron
Figure 1 Serum ferritin in healthy control and children with
IDA after iron therapy.
Table 2 Different clinical and laboratory parameters
before and after iron therapy.
Obese children
with IDA
Non-obese
children with IDA
P
value
(n = 35) (n = 35)
BMI (kg/m2)
Baseline 25.70 ± 2.2 16.30 ± 1.9 <0.01
3 months after Fe
therapy
25.91 ± 2.3 16.22 ± 1.2 <0.01
p value >0.05 >0.05
Hb (g/dl)
Baseline 8.82 ± 1.2 8.22 ± 1.4 >0.05
3 months after Fe
therapy
10.1 ± 0.8 12.8 ± 0.7 <0.05
p value <0.05 <0.05
Serum iron (ug/dl)
Baseline 28.83 ± 2.5 29.28 ± 4.6 >0.05
3 months after Fe
therapy
44.6 ± 6.9 65 ± 8.9 <0.05
p value <0.05 <0.05
TIBC (mg/dl)
Baseline 491 ± 24 478 ± 15 >0.05
3 months after Fe
therapy
385 ± 42 210 ± 23 <0.05
p value <0.05 <0.05
Serum ferritin (ng/ml)
Baseline 51.91 ± 8.7 7.52 ± 1.6 <0.01
3 months after Fe
therapy
52.19 ± 4.1 54.19 ± 4.1 >0.05
p value >0.05 <0.01
Serum hepcidin
(nmol/L)
Baseline 4.96 ± 1.2 0.11 ± 0.03 <0.01
3 months after Fe
therapy
4.56 ± 1.4 1.62 ± 0.6 <0.01
p value >0.05 <0.01
P > 0.05 = non-significant, P < 0.05 = significant, P < 0.01 highly significant.
(Student t test).
Figure 2 Serum hepcidin in healthy control and children with
IDA after iron therapy.
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regulator that causes the hypoferremia and anemia of
chronic disease [33].
In our study, CRP was significantly higher in obese
children with IDA than in non-obese children with
IDA and healthy control group (P < 0.05, respectively).
Meanwhile, there was no significant difference between
non-obese children with IDA and control group as
regard CRP (p > 0.05). Yanoff et al [24] found that CRP
concentrations were higher in obese subjects and were
positively correlated with BMI, findings consistent with
the observation that obesity is an inflammatory state
that increases acute-phase reactants.
In our study, treatment of IDA by oral iron therapy
for three months was associated with significant
improvement of Hb, serum iron and TIBC in cases of
IDA (p < 0.05), that was significantly more evident in
non-obese children than obese children (P < 0.05).
Zimmermann et al [22] stated that adiposity in young
women predicted not only lower iron absorption but
also reduced response to iron supplementation, possibly
due to increased hepcidin production.
In our study, serum ferritin increased significantly in
non-obese children with IDA after 3 months of oral
iron therapy (P < 0.01). On the other hand, obese chil-
dren with IDA showed non-significant change in serum
ferritin before and after oral iron therapy (P > 0.05).
In this study, serum hepcidin increased significantly in
non-obese children with IDA after 3 months of oral
iron therapy (P < 0.01) and reached to normal value in
comparison to healthy control children (Figure 2). On
the other hand, there was non-significant change in
serum hepcidin after oral iron therapy in obese children
(P > 0.01).
The regulation of hepcidin in adipose tissue remains
unknown and may be similar to other adipokines in
subcutaneous and epicardial adipose tissues. Inflamma-
tion-induced hepcidin stimulation is mediated through
IL-6/STAT3 (signal transducer and activator of tran-
scription-3) pathway [17]. On the other hand, mRNA
for hemojuvelin; a surface molecule important for iron
sensing and hepcidin production in the liver [34]; was
not detected in adipose tissue. Hepcidin expression in
adipose tissue is thus stimulated rather by inflammatory
stimuli than by iron [35].
Bariatric surgery resulting in significant and long-last-
ing weight loss reduces inflammation and consequently,
improves iron status in morbidly obese patients [36].
In the present study, serum hepcidin in non-obese
children with IDA, showed significant positive correla-
tion with Hb, serum iron and transferrin saturation (P <
0.01). In contrast, in obese children with IDA, serum
hepcidin showed significant negative correlation with
Hb, serum iron and transferrin saturation (P < 0.05).
Although liver hepcidin expression is positively asso-
ciated with transferrin saturation, adipocyte hepcidin
expression has a positive correlation with BMI, with a
trend toward a negative association with transferrin
saturation [9]. Therefore, lower bioavailability of iron
among obese adults might be potentially related to the
greater adipose hepcidin. Although hepcidin expression
is more than 100-fold higher in hepatocytes than in adi-
pocytes, secreted hepcidin from both tissues may have
relevance for humans because in obesity, adipose tissue
mass may be 20-fold greater than liver mass [24].
It is possible that the proinflammatory cytokines
induced by the obese state increase hepcidin expression
and upregulate ferritin synthesis in the reticuloendothe-
lial cells [27] resulting in diminished absorption of iron
in the setting of increased storage of iron, whether
within the reticuloendothelial system or within adipo-
cytes. Clinically, one would expect this to result in a
combination of nutritional iron deficiency and func-
tional iron deficiency [24]. The limitations of our study
included inability to follow our studied obese children
for a longer time to detect the possibility of delayed
response to iron therapy and whether the reduction of
weight will modify our results but that was due to lack
of cooperation from the patients and their parents.
Finally, we can conclude that obesity increased hepci-
din levels and was associated with diminished response
to oral iron therapy in childhood iron deficiency anemia.
Further studies in larger groups will be required to ver-
ify these findings and to assess the value of weight
reduction in refractory IDA of obese children.
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